Latest Conference Articles

How oncology pharmacists evaluate emerging clinical data, overcome implementation barriers, and stay current with rapidly evolving advances in precision oncology.

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

New breast cancer trial insights reshape metastatic care: sacituzumab benefits broadly, oral SERDs lag, denosumab every 12 weeks suffices.

Niki Shah, MHSA, MBA, CCHW, discusses how Project Oasis, a new diabetic retinopathy screening pilot, and the company's Community Health Worker scholarship program are working together to reduce barriers to care in under-resourced communities

From artificial intelligence (AI)-driven dispensing to specialty service diversification, Jaime Montuoro, PharmD, previews the education lineup at McKesson ideaShare 2026.

Oncology pharmacists decode 2026 ASCO/EHA breakthroughs, from breast cancer to myeloma, highlighting real-world steps for safer, faster care.

The growing role of biomarker-driven treatment selection in breast cancer and how pharmacists can help optimize therapy sequencing, toxicity management, and personalized care.

Key distinctions among bispecific therapies, toxicity management considerations, and the pharmacist’s role in safely implementing these agents across academic and community oncology settings.

Minimal residual disease (MRD) negativity exceeded 90% with 100% response and no progression in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

This is an encore presentation from the 2025 American Pharmacists Association Annual Meeting and Exposition in Nashville, Tennessee. This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Data showed that talquetamab combined with daratumumab, with or without pomalidomide, significantly improved PFS, OS, response rates, and MRD negativity.

Identifying high-risk patients, optimizing lipid-lowering therapy, and helping patients achieve evidence-based targets remain critical to improving cardiovascular outcomes.

The ADA Scientific Sessions highlighted important advances across the diabetes treatment landscape.

Phase 3 REIMAGINE data presented at ADA 2026 show the amylin–GLP-1 combination bests semaglutide monotherapy across type 2 diabetes stages, with implications for pharmacist-managed diabetes care.

TIMI Study Group investigators presented new VESALIUS-CV data showing that intensive LDL-C lowering with evolocumab reduces major cardiovascular events, reinforcing the "lower is better, earlier is better" approach to lipid management.

EHA 2026 data show Sonrotoclax plus zanubrutinib drives rapid, durable uMRD in frontline CLL, even TP53/del17p.

The landscape of cardiovascular prevention is shifting from a focus on surrogate biomarkers to a more granular, image-based assessment of actual disease burden.

Data presented at EHA 2026 continue to support venetoclax plus obinutuzumab as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).

New 2026 lipid guidelines push earlier screening, PREVENT risk scoring, and tougher LDL/ApoB targets with expanded nonstatin options.

New data from the phase 3 DeLLphi-304 trial suggest tarlatamab significantly improves intracranial efficacy outcomes, CNS progression-free survival, and overall survival in patients with relapsed small cell lung cancer (SCLC) and baseline brain metastases.

Jessica Dunne, PhD, discusses why adult type 1 diabetes (T1D) is frequently misdiagnosed as T2D in patients with gestational diabetes mellitus (GDM) and how autoantibody testing could close the diagnostic gap.

Phase 3 frontMIND phase 3 trial data show tafasitamab plus lenalidomide with R-CHOP boosts PFS and has manageable safety in high-risk newly diagnosed DLBCL.

Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA, highlights key data and events at the 2026 NLA Scientific Sessions.

High-dose oral semaglutide pills boost A1C control and double-digit weight loss in diabetes and obesity trials, offering injectable-level results with daily convenience.

Jessica Dunne, PhD, discusses why adult T1D is frequently misdiagnosed as T2D and how autoantibody testing could close the diagnostic gap.